EC
TRML

EntryPoint Capital’s Tourmaline Bio TRML Stock Holding History

EntryPoint Capital’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,966
Closed -$223K – 873
2025
Q2 		$223K Sell
13,966
-11,006
-44% -$178K 0.11% 426
2025
Q1 		$380K Buy
+24,972
New +$400K 0.17% 201

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

EntryPoint Capital's TRML Position: Q3 2025 in Review

EntryPoint Capital sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 13,966 shares — an estimated $223K sold.

EntryPoint Capital first reported a position in TRML in Q1 2025 and held it in 2 quarters. The position peaked at $380K in Q1 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • EntryPoint Capital reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • EntryPoint Capital sold 13,966 Tourmaline Bio shares in Q3 2025, an estimated $223K.
  • EntryPoint Capital first reported a position in Tourmaline Bio in Q1 2025 and held it in 2 quarters.
  • EntryPoint Capital's Tourmaline Bio position peaked at $380K in Q1 2025.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.